Skip to main content

Table 1 Overview of patient and treatment characteristics

From: Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)

age at diagnosis (years)

median (range)

54 (34–73)

surgical procedure

biopsy resection

1/10 (10%)

9/10 (90%)

total RT dose (Gy)

median (range)

54 (45–60.6)

adjuvant chemotherapy with ACNU/VM26

 

8/10 (80%)

no. of adjuvant cycles

median (range)

3.5 (1–6)

≥ 4 adjuvant cycles

 

4/10 (40%)

  1. Overview of patient and treatment characteristics for n = 10 consecutive patients with glioblastoma multiforme with oligodendroglial component (GBMO).